Add to Favorites
Alternative Name
Targeted Solid Tumor Fusion Panel
Test Description

The Targeted Solid Tumor NGS Fusion Panel is an RNA-based next-generation sequencing panel that detects translocations and fusions with known and novel fusion partners of these genes: ALK, BRAF, FGFR1, FGFR2, FGFR3, FGFR4, MET Exon 14 skipping, NOTCH1, NOTCH2, NRG1, NTRK1, NTRK2, NTRK3, PDGFB, PDGFRA, PDGFRB, RAF1, RET, and ROS1.

Clinical Significance

Gene fusion events that deregulate protein expression or generate a chimeric protein are associated with the pathology of several cancer types. The Targeted Solid Tumor NGS Fusion Panel is intended to identify gene fusions that have been reported as oncogenic drivers in multiple solid tumors, including but not limited to NSCLC, urothelial carcinoma, cholangiocarcinoma, and thyroid carcinoma. Patients with the gene fusions may respond to select kinase inhibitors that have been approved by the FDA, including crizotinib, ceritinib, imatinib, larotrectinib, entrectinib, pemigatinib, and selpercatinib.

Specimen Requirements
  • FFPE tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Storage and Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

CPT Code(s)*
New York Approved
Level of Service
Turnaround Time

21 Days

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.